(Stroke. 1999;30:834-840.)
© 1999 American Heart Association, Inc.
Original Contributions |
From the Mayo Clinic Jacksonville, Jacksonville, Fla (J.L.B); Statistics and Epidemiology Research Corporation, Seattle, Wash (L.A.P.); University of Texas Health Science Center, San Antonio, Tex (R.G.H., M.Z.); St Louis University Medical Center, St Louis, Mo (A.L.); Hennepin County Medical Center, Minneapolis, Minn (R.W.A.); and Mt Sinai Medical Center, New York, NY (J.L.H.).
Correspondence to Joseph L. Blackshear, MD, Division of Cardiovascular Diseases, Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224. E-mail jlb16{at}exjax.mayo.edu
| Abstract |
|---|
|
|
|---|
MethodsThoracic aortic plaque was prospectively sought in 770
persons with AF with the use of transesophageal
echocardiography and classified as simple or
complex on the basis of thickness
4 mm, ulceration, or mobility.
Clinical and echocardiographic features of
thromboembolism were correlated by multivariate
analysis.
ResultsAortic plaque was detected in 57% of the cohort, and
complex plaque was detected in 25%. Both were found more frequently in
the descending than in the proximal aorta. Potentially etiologic
patient characteristics independently associated with complex plaque
included advanced age, history of hypertension, diabetes, and past or
present tobacco use. Comorbidities associated with aortic plaque
were prior thromboembolism, increased pulse pressure, ischemic
heart disease, stenosis or sclerosis of the aortic valve,
mitral annular calcification (>10%), elevated serum
creatinine concentration, spontaneous echo contrast in the
left atrium or appendage, and left atrial appendage thrombus. The
prevalence of complex plaque in patients aged <70 years with <10%
mitral annular calcification, without ischemic heart disease,
or without pulse pressure
65 mm Hg was 4% (95% CI, 1% to
6%).
ConclusionsAortic plaque is prevalent in patients with AF and is associated with atherosclerosis risk factors and with left atrial stasis or thrombosis, which are themselves independent stroke risk factors. Since the predominant location of complex plaque was in the descending aorta, the role of aortic plaque as a source of embolism in AF is uncertain.
Key Words: aorta atherosclerosis atrial fibrillation
| Introduction |
|---|
|
|
|---|
We report the prevalence and predictors of aortic plaque and plaque with complex features in the largest cohort of AF patients prospectively evaluated for plaque. The results suggest a confluence of cardioembolic and vascular factors that contribute to thromboembolism in patients with AF.
| Subjects and Methods |
|---|
|
|
|---|
1 of the following risk factors: prior
thromboembolism, systolic blood pressure >160 mm Hg,
recent heart failure or fractional shortening
25%, or female sex and
aged >75 years. Details of the design, patient selection criteria, and
main results have been reported elsewhere.4 7 8 9
All patients were encouraged to undergo TEE within 3 months of
enrollment, and consent was obtained from 382 of 1044 high-risk
patients and 404 of 892 low-risk patients. The technique for TEE
acquisition and criteria for interpretation,10
interobserver reliability for assessment of variables, including
aortic plaque, and TEE correlates of thromboembolic risk have also been
published.4 11 Atherosclerotic plaque in the thoracic
aorta was categorized in terms of location and morphology. The aorta
was divided into ascending, transverse, and descending segments, and
plaque was classified as simple (sessile) or complex on the basis of
thickness
4 mm, ulceration, pedunculation, or mobile
elements.10
Risk factors for atherosclerosis and risk factors for
thromboembolism in AF patients were identified and divided into
potentially etiologic patient characteristics and associated patient
characteristics for atherosclerotic plaque before the start of
analyses. Results for all variables evaluated are reported.
Characteristics were compared between groups with Student's
t test for continuous variables and a
2 test for categorical variables. Two
series of multivariate analyses comparing any
versus no plaque, and no plaque versus simple versus complex plaque,
were done to identify (1) independent potentially etiologic predictors
and (2) independent associated characteristics. A third series was done
to identify independent etiologic and associated characteristics to
derive a predictive scheme for complex plaque. Stepwise logistic
regression and stepwise polychotomous logistic regression techniques
were used (likelihood ratio test). The 75th percentile was used as the
cut point for any continuous variable in the predictive scheme.
Statistical significance was accepted at the 0.05 level, and all tests
were 2-sided.
| Results |
|---|
|
|
|---|
|
|
Patients at high risk of thromboembolism on the basis of clinical
and precordial echocardiographic criteria were more
likely to have aortic plaque than low-risk patients (complex in 35%
versus 15%; P<0.001). Univariate variables
potentially related to aortic plaque are listed in Table 2
. Multivariate
analysis identified age as an independent, potentially
etiologic predictor of simple and complex plaque, while tobacco
smoking, hypertension, and diabetes were independently associated with
complex plaque alone (Table 3
). Complex
plaque was not related to sex, random serum cholesterol
levels, or fibrinogen. Of the associated patient characteristics,
increased pulse pressure, aortic valve disease, and left atrial
spontaneous echo contrast and thrombus were associated with both simple
and complex plaque (Table 3
). Prior thromboembolism (relative
risk, 2.9; 95% CI, 1.9 to 4.6; P<0.001) and mitral annular
calcification >10% (relative risk, 3.3; 95% CI, 1.8 to 6.0;
P<0.001) were strongly associated with complex plaque
alone.
|
|
Multivariate analysis of both etiologic
features and comorbidities (Table 4
)
confirmed the strong association of tobacco smoking, prior
thromboembolism, and mitral annular calcification >10% with complex
aortic plaque (all P<0.001). Although the prevalence of
plaque varied by segment, these predictors of simple and complex plaque
were confirmed at all sites. The prevalence of complex plaque was 4%
(95% CI, 1% to 6%) among patients <70 years of age without the
following: ischemic heart disease, pulse pressure
65
mm Hg, or mitral annular calcification >10% (31% of the
cohort). Current tobacco smoking in a patient with any of these
4 predictive characteristics raised the prevalence of complex plaque to
>50% to approach that associated with prior thromboembolism (Figure 2
). Increased left
ventricular mass appeared associated with reduced plaque,
but this finding was restricted to persons aged >70 years who lacked
other characteristics associated with aortic plaque.
|
|
| Discussion |
|---|
|
|
|---|
12%/y) can be estimated only within broad confidence limits,
however, both in patients with AF11 and in those without
this dysrhythmia.13 14 15 The sonographic morphology of
these atherosclerotic lesions is related to the risk of
stroke13 in that patients with complex plaques are at
almost twice the risk of those without this configuration. In patients
with AF at high risk of thromboembolism who have complex aortic plaque,
the rate of stroke among those treated by anticoagulation with
adjusted-dose warfarin was one fourth the rate seen with a
low-intensity combination of warfarin and aspirin.4 While
this reduction in stroke among anticoagulated AF patients may have been
due to disappearance of thrombus in the left atrial
appendage,16 the rate of thromboembolism was also low
(<2% annually; 95% CI, 0.2% to 8.7%/y) in similar high-risk AF
patients without plaque who were not adequately
anticoagulated.4 This implies a role but does not define a
site for cardiac or arterial thrombosis in the risk of
stroke associated with complex aortic plaque in the AF population.
Classification, Prevalence, and Location of Aortic Plaque
Complex aortic plaques are so designated by thickness or in terms
of surface abnormalities. Mobile components are usually
thrombi17 18 that vary with time and location. Aortic
plaque was found proximal to the left subclavian artery on postmortem
examination in 60% of elderly stroke victims,19 and
despite a sonographic "blind spot" in the upper ascending aorta,
this was almost the same prevalence at which it was detected by TEE in
patients with nonfatal stroke (55% to 57%).1 3
Atheromatous lesions are more common in the descending
versus ascending or transverse arch portions of the thoracic aorta.
Amarenco et al1 found plaque in the descending aortas of
>90% of patients with prior stroke; the prevalence of complex plaque
in this segment was 24%. The recurrent stroke rate in patients
with complex lesions in the proximal aorta was >10%/y, and vascular
events in these patients (stroke, myocardial infarction,
peripheral embolism, death from vascular cause) occurred at
approximately twice the rate of recurrent embolism.14 15
Among patients undergoing TEE during coronary bypass or
valvular heart surgery, >50% displayed plaque in the aorta,
33% in the proximal and transverse segments, and >40% in the
descending limb. Complex lesions occurred in 16%, and
perioperative stroke rates correlated with the
prevalence of complex plaque in the descending aorta.20 21
The prevalence of complex plaque in the ascending and transverse aortic
segments in our AF patients, 12%, falls near the lower end of the
range described in studies of stroke patients (14% to
42%),1 3 22 23 and parallels thromboembolic risk defined
on the basis of clinical criteria. Complex plaque at any site was
detected in 15% of low-risk patients and 35% of high-risk patients,
similar to the prevalence reported in patients with AF referred for TEE
(half of whom had prior clinical thromboembolism) (Table 5
).24 25 26 In
contrast, carotid artery stenosis has been reported less
frequently in AF patients (8%; range, 4% to 17%).27
|
Predictors of Aortic Plaque
In unselected stroke patients, complex plaque in the ascending or
transverse segments was associated with peripheral and
carotid arterial disease as well as with age, tobacco
smoking, and diabetes.3 14 In patients undergoing cardiac
surgery because of ischemic or valvular disease, serum
cholesterol, plasma fibrinogen, and small body mass were
additional predictors of complex plaque.21 28 In our broad
population of AF patients, we determined that age, tobacco smoking,
pulse pressure, and thrombus in the left atrial appendage were
independently associated with plaque, both simple and complex.
Additional patient features that predicted complex plaque included
prior thromboembolism, ischemic heart disease, diabetes, and
moderate to severe mitral annular calcification, all variables
independently associated with stroke in patients with or without
AF.4 29 30 31 Calcific disease of the aortic valve was also
independently associated. Aortic valve disease has previously been
linked to atherosclerotic risk factors, but not stroke
risk.32 AF patients aged >70 years with ischemic
heart disease, mitral annular calcification >10%, and
arterial pulse pressure
65 mm Hg were most likely
to display complex aortic plaque.
Although hypertension and increased pulse pressure were strongly associated with complex aortic plaque, left ventricular mass was inversely related in older patients without other characteristics associated with complex plaque. This paradox is consistent with observations at autopsy. In victims of cryptogenic cerebral infarction,19 cardiac mass was lower (388±109 versus 427±108 g; P=0.08) and proximal aortic plaque was more prevalent (61% versus 22%; odds ratio, 5.7; 95% CI, 2.5 to 13.6) than in those in whom an embolic source was identified. An inverse relationship between aortic plaque and cardiac mass might mean that AF patients who adapt to aging with development of myocardial hypertrophy have a reduced tendency to develop aortic atherosclerosis versus those who do not develop hypertrophy. Opposite responses in cardiac muscle and arterial wall might reflect genetically mediated adaptive differences, which are now under active investigation.33 34 35 36
Study Limitations
TEE was performed in willing patients at entry into this clinical
trial, but fewer than 50% of the total patients underwent TEE, raising
the possibility that our findings may not represent either the
SPAF III population overall or an AF population in general. The SPAF
III TEE population is not dissimilar to the Atrial Fibrillation
Investigators population of 4253 AF patients in terms of mean age (69
years), history of hypertension (45%), angina (23%), or congestive
heart failure (20%).37 These data suggest that the SPAF
III TEE population is similar in most respects to prior AF clinical
trial populations, who are, admittedly, selected
populations.38
The existence of a sonographic blind spot in the aorta (upper ascending aorta) is an additional limitation in an analysis that seeks to define plaque prevalence and describe a source of embolism. Finally, the potentially etiologic and associated variables selected for analysis were based on current concepts of pathogenesis. Chance association of selected variables with plaque or failure of selection of relevant variables for analysis cannot be excluded.
Implications of Aortic Plaque in AF
Although the prevalence of complex aortic plaque in patients with
AF raises the possibility that plaque-associated thrombus may be a
direct cause of embolism in AF, such a mechanism has not been proven.
In prior studies in which most plaques were found in the proximal
aorta, both cerebral and peripheral emboli occurred, while
in our patients with complex plaque limited to the descending aorta,
clinical ischemic events exclusively involved the central
nervous system (Figure 3
).13 14 15 39 40 The paucity
of peripheral ischemic events in our treated
patients suggests that plaque-related embolism is not the dominant
mechanism of thromboembolism in AF. Endocardial and left atrial
abnormalities (thrombus, spontaneous echo contrast, and reduced
appendage flow velocity) were more prevalent in patients with complex
aortic plaque than in those without plaque. The rate of thromboembolism
was low among patients without plaque treated with the relatively
ineffective combination of low-dose warfarin plus aspirin (1.2%/y;
95% CI, 0.2% to 8.7%).4 In contrast, those with complex
plaque had a high risk of stroke (16%/y; 95% CI, 8.7% to 28%),
unless treated more intensively with adjusted-dose warfarin (4.0%/y;
95% CI, 1.3% to 12%).4 This association of complex
plaque with thromboembolic risk may be mediated by left atrial or
endocardial abnormalities in patients with AF.
|
| Acknowledgments |
|---|
Received October 19, 1998; revision received December 22, 1998; accepted December 28, 1998.
| References |
|---|
|
|
|---|
2.
Amarenco P, Cohen A, Hommel M, Bousser M.
Atherosclerotic disease of the aortic arch and the risk of
ischemic stroke. N Engl J Med. 1995;332:12371238.
3. Jones EF, Kalman JM, Calafiore P, Tonkin AM, Donnan GA. Proximal aortic atheroma: an independent risk factor for cerebral ischemia. Stroke. 1995;26:218224.
4.
Stroke Prevention in Atrial Fibrillation Investigators
Committee on Echocardiography.
Transesophageal echocardiographic
correlates of thromboembolism in high-risk patients with
nonvalvular atrial fibrillation. Ann Intern Med. 1998;128:639647.
5.
Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart
RG, Anderson DC, on behalf of the Stroke Prevention in Atrial
Fibrillation investigators. Ischemic stroke in patients with
atrial fibrillation: effect of aspirin according to stroke mechanism.
Neurology. 1993;43:3236.
6.
Manning WJ, Douglas PS.
Transesophageal echocardiography
and atrial fibrillation: added value or expensive toy? Ann Intern
Med. 1998;128:685687.
7. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation III randomized clinical trial: background, design and patient characteristics of the Stroke Prevention in Atrial Fibrillation III study. J Stroke Cerebrovasc Dis. 1997;6:341353.[Medline] [Order article via Infotrieve]
8. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633638.[Medline] [Order article via Infotrieve]
9.
Stroke Prevention in Atrial Fibrillation III Study
Investigators. Patients with nonvalvular atrial fibrillation at
low risk of stroke during treatment with aspirin: Stroke Prevention in
Atrial Fibrillation Study. JAMA. 1998;279:12731277.
10. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiography in atrial fibrillation: standards for acquisition and interpretation and assessment of interobserver variability. J Am Soc Echocardiogr. 1996;9:556566.[Medline] [Order article via Infotrieve]
11.
Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL,
Asinger RW, Hart RG, for the Stroke Prevention in Atrial Fibrillation
III Investigators. Transesophageal
echocardiographic correlates of clinical risk of
thromboembolism in nonvalvular atrial fibrillation.
J Am Coll Cardiol. 1998;31:16221626.
12. Tunick PA, Kronzon I. Protruding atherosclerotic plaque in the aortic arch of patients with systemic embolization: a new finding seen by transesophageal echocardiography. Am Heart J. 1990;120:658660.[Medline] [Order article via Infotrieve]
13. Tunick PA, Rosenzweig BP, Katz ES, Freedberg RS, Perez JL, Kronzon I. High risk for vascular events in patients with protruding aortic atheromas: a prospective study. J Am Coll Cardiol. 1994;23:10851090.[Abstract]
14.
The French Study of Aortic Plaques in Stroke Group.
Atherosclerotic disease of the aortic arch as a risk factor for
recurrent ischemic stroke. N Engl J Med. 1996;334:12161221.
15.
Mitusch R, Doherty C, Wucherpfennig H, Memmesheimer C,
Tepe C, Stierle U, Kessler C, Sheikhzadeh A. Vascular events during
follow-up in patients with aortic arch atherosclerosis.
Stroke. 1997;28:3639.
16.
Collins LJ, Silverman DI, Douglas PS, Manning WJ.
Cardioversion of nonrheumatic atrial fibrillation: reduced
thromboembolic complications with 4 weeks of precardioversion
anticoagulation are related to atrial thrombus resolution.
Circulation. 1995;92:160163.
17.
Kronzon I, Tunick PA. Atheromatous
disease of the thoracic aorta: pathologic and clinical implications.
Ann Intern Med. 1997;126:629637.
18. Vaduganathan P, Ewton A, Nagueh SF, Weilbaecher DG, Safi HJ, Zoghbi WA. Pathologic correlates of aortic plaques, thrombi and mobile "aortic debris" imaged in vivo with transesophageal echocardiography. J Am Coll Cardiol. 1997;30:357363.[Abstract]
19. Amarenco P, Duyckaerts C, Tzourio C, Henin D, Bousser MG, Hauw JJ. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med. 1992;326:221225.[Abstract]
20. Dávila-Román VG, Barzilai B, Wareing TH, Murphy SF, Schechtman KB, Kouchoukos NT. Atherosclerosis of the ascending aorta: prevalence and role as an independent predictor of cerebrovascular events in cardiac patients. Stroke. 1994;25:20102016.[Abstract]
21. Hartman GS, Yao FS, Bruefach M III, Barbut D, Peterson JC, Purcell MH, Charlson ME, Gold JP, Thomas SJ, Szatrowski TP. Severity of aortic atheromatous disease diagnosed by transesophageal echocardiography predicts stroke and other outcomes associated with coronary artery surgery: a prospective study. Anesth Analg. 1996;83:701708.[Abstract]
22.
Toyoda K, Yasaka M, Nagata S, Yamaguchi T. Aortogenic
embolic stroke: a transesophageal
echocardiographic approach. Stroke. 1992;23:10561061.
23.
Di Tullio MR, Sacco RL, Gersony D, Nayak H, Weslow RG,
Kargman DE, Homma S. Aortic atheromas and acute
ischemic stroke: a transesophageal
echocardiographic study in an ethnically mixed
population. Neurology. 1996;46:15601566.
24. Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1994;24:755762.[Abstract]
25. Mitusch R, Lange V, Stierle U, Maurer B, Sheikhzadeh A. Transesophageal echocardiographic determinants of embolism in nonrheumatic atrial fibrillation. Int J Card Imaging. 1995;11:2734.[Medline] [Order article via Infotrieve]
26. Pozzoli M, Tramarin R, Gibellini R, Ferrari-Bardile A, Capomolla S, Forni G, Sanarico M, Cobelli F. Cardiac and vascular sources of peripheral thromboembolism in patients with atrial fibrillation: a combined transesophageal and vascular ultrasonographic study. G Ital Cardiol. 1995;25:301314.[Medline] [Order article via Infotrieve]
27.
Kanter MC, Tegeler CH, Pearce LA, Weinberger J,
Feinberg WM, Anderson DC, Gomez CR, Rothrock JF, Helgason CM, Hart RG.
Carotid stenosis in patients with atrial fibrillation:
prevalence, risk factors, and relationship to stroke in the Stroke
Prevention in Atrial Fibrillation Study. Arch Intern Med. 1994;154:13721377.
28. Tribouilloy C, Peltier M, Colas L, Senni M, Ganry O, Rey JL, Lesbre JP. Fibrinogen is an independent marker for thoracic aortic atherosclerosis. Am J Cardiol. 1998;81:321326.[Medline] [Order article via Infotrieve]
29. Aronow WS, Ahn C, Kronzon I, Gutstein H. Association of mitral annular calcium with new thromboembolic stroke at 44-month follow-up of 2,148 persons, mean age 81 years. Am J Cardiol. 1998;81:105106.[Medline] [Order article via Infotrieve]
30.
Atrial Fibrillation Investigators. Risk factors for
stroke and efficacy of antithrombotic therapy in atrial fibrillation:
analysis of pooled data from five randomized controlled trials.
Arch Intern Med. 1994;154:14491457.
31. Adler Y, Shohat-Zabarski R, Vaturi M, Shapira Y, Ehrlich S, Jortner R, Assali A, Zonshin A, Sagie A. Association between mitral annular calcium and aortic atheroma as detected by transesophageal echocardiographic study. Am J Cardiol. 1998;81:784786.[Medline] [Order article via Infotrieve]
32.
Boon A, Lodder J, Cheriex E, Kessels F. Risk of stroke
in a cohort of 815 patients with calcification of the aortic valve with
or without stenosis. Stroke. 1996;27:847851.
33. Lehmann ED, Hopkins KD, Jones RL, Rudd AG, Gosling RG. Aortic distensibility in patients with cerebrovascular disease. Clin Sci (Colch). 1995;89:247253.[Medline] [Order article via Infotrieve]
34.
Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi
MA, Hemingway H, Statters D, Jubb M, Girvain M, Varnava A, World M,
Deanfield J, Talmud P, McEwan JR, McKenna WJ, Humphries S. Association
of angiotensin-converting enzyme gene I/D polymorphism
with change in left ventricular mass in response to
physical training. Circulation. 1997;96:741747.
35.
Schunkert H, Hense HW, Holmer SR, Stender M, Perz S,
Keil U, Lorell BH, Riegger GA. Association between a deletion
polymorphism of the angiotensin-converting-enzyme gene
and left ventricular hypertrophy. N
Engl J Med. 1994;330:16341638.
36.
Benetos A, Gautier S, Ricard S, Topouchian J, Asmar R,
Poirier O, Larosa E, Guize L, Safar M, Soubrier F, Cambien F. Influence
of angiotensin-converting enzyme and
angiotensin II type 1 receptor gene polymorphisms on
aortic stiffness in normotensive and hypertensive patients.
Circulation. 1996;94:698703.
37.
Atrial Fibrillation Investigators.
Echocardiographic predictors of stroke in patients with
atrial fibrillation: a prospective study of 1066 patients from 3
clinical trials. Arch Intern Med. 1998;158:13161320.
38. Blackshear JL, Kopecky SL, Litin SC, Safford RE, Hammill SC. Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Mayo Clin Proc. 1996;71:150160.[Abstract]
39. Tunick PA, Perez JL, Kronzon I. Protruding atheromas in the thoracic aorta and systemic embolization. Ann Intern Med. 1991;115:423427.
40. Karalis DG, Chandrasekaran K, Victor MF, Ross JJ Jr, Mintz GS. Recognition and embolic potential of intraaortic atherosclerotic debris. J Am Coll Cardiol. 1991;17:7378.[Abstract]
This article has been cited by other articles:
![]() |
R. P. Whitlock, J. S. Healey, and S. J. Connolly Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin Circulation, November 10, 2009; 120(19): 1927 - 1932. [Full Text] [PDF] |
||||
![]() |
U. Kalyoncu, O. Dizdar, A. Erkan Duman, O. Karadag, A. Tufan, O. Yucel, O. Tayfur, D. Sen, Z. Ulger, A. Kepez, et al. Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation Clinical and Applied Thrombosis/Hemostasis, February 1, 2009; 15(1): 103 - 108. [Abstract] [PDF] |
||||
![]() |
K. E. Glas, M. Swaminathan, S. T. Reeves, J. S. Shanewise, D. Rubenson, P. K. Smith, J. P. Mathew, S. K. Shernan, and Council for Intraoperative Echocardiography of the Guidelines for the Performance of a Comprehensive Intraoperative Epiaortic Ultrasonographic Examination: Recommendations of the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists; Endorsed by the Society of Thoracic Surgeons Anesth. Analg., May 1, 2008; 106(5): 1376 - 1384. [Full Text] [PDF] |
||||
![]() |
S. Sen, A. Hinderliter, P. K. Sen, J. Simmons, J. Beck, S. Offenbacher, E. M. Ohman, and S. M. Oppenheimer Aortic Arch Atheroma Progression and Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack Circulation, August 21, 2007; 116(8): 928 - 935. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Thambidorai, S. J. Jaffer, T. K. Shah, W. J. Stewart, A. L. Klein, and M. S. Lauer Association of atheroma as assessed by intraoperative transoesophageal echocardiography with long-term mortality in patients undergoing cardiac surgery Eur. Heart J., June 6, 2007; (2007) ehm180v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Dentali, J. D. Douketis, W. Lim, and M. Crowther Combined Aspirin-Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease: A Meta-analysis of Randomized Trials Arch Intern Med, January 22, 2007; 167(2): 117 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): 854 - 906. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): 700 - 752. [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Eur. Heart J., August 2, 2006; 27(16): 1979 - 2030. [Full Text] [PDF] |
||||
![]() |
S. V. Lichtenstein Closed heart surgery: Back to the future J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 941 - 943. [Full Text] [PDF] |
||||
![]() |
I. Meissner, B. K. Khandheria, S. G. Sheps, G. L. Schwartz, D. O. Wiebers, J. P. Whisnant, J. L. Covalt, T. M. Petterson, T. J.H. Christianson, and Y. Agmon Atherosclerosis of the aorta: Risk factor, risk marker, or innocent bystander?: A prospective population-based transesophageal echocardiography study J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1018 - 1024. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sen, S. M. Oppenheimer, V. Gupta, and N. C. Nanda Racial Differences in Aortic Plaque Among Ischemic Stroke Patients Stroke, July 1, 2003; 34 (7): e76 - e76. [Full Text] [PDF] |
||||
![]() |
R. E. Murphy, A. R. Moody, P. S. Morgan, A. L. Martel, G.S. Delay, S. Allder, S. T. MacSweeney, W. G. Tennant, J. Gladman, J. Lowe, et al. Prevalence of Complicated Carotid Atheroma as Detected by Magnetic Resonance Direct Thrombus Imaging in Patients With Suspected Carotid Artery Stenosis and Previous Acute Cerebral Ischemia Circulation, June 24, 2003; 107(24): 3053 - 3058. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Hart, J. L. Halperin, L. A. Pearce, D. C. Anderson, R. A. Kronmal, R. McBride, E. Nasco, D. G. Sherman, R. L. Talbert, J. R. Marler, et al. Lessons from the Stroke Prevention in Atrial Fibrillation Trials Ann Intern Med, May 20, 2003; 138(10): 831 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Fox, R. S. Vasan, H. Parise, D. Levy, C. J. O'Donnell, R. B. D'Agostino, and E. J. Benjamin Mitral Annular Calcification Predicts Cardiovascular Morbidity and Mortality: The Framingham Heart Study Circulation, March 25, 2003; 107(11): 1492 - 1496. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Albahrani, M. Swaminathan, B. Phillips-Bute, P. K. Smith, M. F. Newman, J. P. Mathew, and M. Stafford-Smith Postcardiac Surgery Complications: Association of Acute Renal Dysfunction and Atrial Fibrillation Anesth. Analg., March 1, 2003; 96(3): 637 - 643. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S.G. Conway, L. A. Pearce, B. S.P. Chin, R. G. Hart, and G. Y.H. Lip Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 1321 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors Circulation, October 8, 2002; 106(15): 1962 - 1967. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Fasseas, E. S. Brilakis, B. Leybishkis, M. Cohen, A. B. Sokil, N. Wolf, R. L. Dorn, A. Roberts, and W. VanDecker Association of Carotid Artery Intima-Media Thickness with Complex Aortic Atherosclerosis in Patients with Recent Stroke Angiology, March 1, 2002; 53(2): 185 - 189. [Abstract] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology Circulation, October 23, 2001; 104(17): 2118 - 2150. [Full Text] [PDF] |
||||
![]() |
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923. [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1231 - 1265. [Full Text] [PDF] |
||||
![]() |
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266. [Full Text] [PDF] |
||||
![]() |
Y. Agmon, B. K. Khandheria, I. Meissner, J. D. Sicks, W. M. O'Fallon, D. O. Wiebers, J. P. Whisnant, J. B. Seward, and A. J. Tajik Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease?: Insights from a population-based study J. Am. Coll. Cardiol., September 1, 2001; 38(3): 827 - 834. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Shinokawa, T. Hirai, S. Takashima, T. Kameyama, K. Nakagawa, H. Asanoi, and H. Inoue A Transesophageal Echocardiographic Study on Risk Factors for Stroke in Elderly Patients With Atrial Fibrillation : A Comparison With Younger Patients Chest, September 1, 2001; 120(3): 840 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Chugh, J. L. Blackshear, W.-K. Shen, S. C. Hammill, and B. J. Gersh Epidemiology and natural history of atrial fibrillation: clinical implications J. Am. Coll. Cardiol., February 1, 2001; 37(2): 371 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Agmon, B. K. Khandheria, I. Meissner, G. L. Schwartz, T. M. Petterson, W. M. O'Fallon, F. Gentile, J. P. Whisnant, D. O. Wiebers, and J. B. Seward Independent Association of High Blood Pressure and Aortic Atherosclerosis : A Population-Based Study Circulation, October 24, 2000; 102(17): 2087 - 2093. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Iribarren, S. Sidney, B. Sternfeld, and W. S. Browner Calcification of the Aortic Arch: Risk Factors and Association With Coronary Heart Disease, Stroke, and Peripheral Vascular Disease JAMA, June 7, 2000; 283(21): 2810 - 2815. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Hart and J. L. Halperin Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention Ann Intern Med, November 2, 1999; 131(9): 688 - 695. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |